Your browser doesn't support javascript.
loading
PRNP is a pan-cancer prognostic and immunity-related to EMT in colorectal cancer.
Chen, Haifeng; Du, Yao; Kong, Zhiyuan; Liao, Xinghe; Li, Weiping.
Affiliation
  • Chen H; Department of Gastroenterology, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, China.
  • Du Y; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
  • Kong Z; Department of Gastrointestinal Surgery, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, China.
  • Liao X; Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Li W; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Front Cell Dev Biol ; 12: 1391873, 2024.
Article de En | MEDLINE | ID: mdl-39170916
ABSTRACT

Background:

Prion protein gene (PRNP) is widely expressed in a variety of tissues. Although the roles of PRNP in several cancers have been investigated, no pan-cancer analysis has revealed its relationship with tumorigenesis and immunity.

Methods:

Comprehensive analyses were conducted on The Cancer Genome Atlas (TCGA) Pan-Cancer dataset from the University of California Santa Cruz (UCSC) database to determine the expression of PRNP and its potential prognostic implications. Immune infiltration and enrichment analysis methods were used to ascertain correlations between PRNP expression levels, tumor immunity, and immunotherapy. Additionally, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) methods were employed to examine possible signaling pathways involving PRNP. In vitro experiments using CCK-8 assay, Wound healing assay, and Transwell assay to detect the effect of Cellular prion protein (PrPC) on proliferation, migration, and invasion in colorectal cancer (CRC) cells. The expression levels of epithelial-mesenchymal transition (EMT)-related proteins (N-cadherin, E-cadherin, Vimentin and Snail) were detected by western blot.

Results:

Among most cancer types, PRNP is expressed at high levels, which is linked to the prognosis of patients. PRNP expression is strongly associated with immune infiltrating cells, immunosuppressive cell infiltration and immune checkpoint molecules. In addition to tumor mutation burden (TMB), substantial correlations are detected between PRNP expression and microsatellite instability (MSI) in several cancers. In vitro cell studies inferred that PrPC enhanced the proliferation, migration, invasion, and EMT of CRC cells.

Conclusion:

PRNP serves as an immune-related prognostic marker that holds promise for predicting outcomes related to CRC immunotherapy while simultaneously promoting cell proliferation, migration, and invasion activities. Furthermore, it potentially plays a role in governing EMT regulation within CRC.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Cell Dev Biol Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Cell Dev Biol Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse